Search research articles
Contact Us
Filters
Showing results (11-20 of 52) with videos related to
Page
of 6
Sort By:
Blood Advances
|
July 18, 2024
A budget impact analysis of gene therapy for sickle cell disease: an updated analysis
Patrick C DeMartino, Meredith B Haag, Aaron B Caughey, et al.
JAMA Oncology
|
March 25, 2016
Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies
Joshua A Roth, Roman Gulati, John L Gore, et al.
The Oncologist
|
April 9, 2014
Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer
Joshua A Roth, Paul Billings, Scott D Ramsey, et al.
Journal of Managed Care & Specialty Pharmacy
|
April 25, 2020
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer
Joshua A Roth, Josh J Carlson, Fang Xia, et al.
Expert Opinion on Biological Therapy
|
January 27, 2026
A situational analysis of the adoption of oncology, inflammation, and supportive care biosimilars in the United States
Bhavesh Shah, Josephine Kim, Ann Wicker, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 6, 2025
The Price Effects of Biosimilars in the United States
Mireia Jofre-Bonet, Alistair McGuire, Victoria Dayer, et al.
Pharmacoepidemiology and Drug Safety
|
April 11, 2015
Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting
Joshua A Roth, Katharine Bradley, Kenneth E Thummel, et al.
Journal of Managed Care & Specialty Pharmacy
|
November 30, 2020
THE AUTHORS RESPOND
Joshua A Roth, Josh J Carlson, Fang Xia, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
September 3, 2010
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice
David L Veenstra, Joshua A Roth, Louis P Garrison, et al.
Advances in Therapy
|
May 7, 2022
Correction to: Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer
Jesse A Sussell, Joshua A Roth, Craig S Meyer, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 52) with videos related to
Sort By:
Page
of 6
Blood Advances
|
July 18, 2024
A budget impact analysis of gene therapy for sickle cell disease: an updated analysis
Patrick C DeMartino, Meredith B Haag, Aaron B Caughey, et al.
JAMA Oncology
|
March 25, 2016
Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies
Joshua A Roth, Roman Gulati, John L Gore, et al.
The Oncologist
|
April 9, 2014
Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer
Joshua A Roth, Paul Billings, Scott D Ramsey, et al.
Journal of Managed Care & Specialty Pharmacy
|
April 25, 2020
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer
Joshua A Roth, Josh J Carlson, Fang Xia, et al.
Expert Opinion on Biological Therapy
|
January 27, 2026
A situational analysis of the adoption of oncology, inflammation, and supportive care biosimilars in the United States
Bhavesh Shah, Josephine Kim, Ann Wicker, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 6, 2025
The Price Effects of Biosimilars in the United States
Mireia Jofre-Bonet, Alistair McGuire, Victoria Dayer, et al.
Pharmacoepidemiology and Drug Safety
|
April 11, 2015
Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting
Joshua A Roth, Katharine Bradley, Kenneth E Thummel, et al.
Journal of Managed Care & Specialty Pharmacy
|
November 30, 2020
THE AUTHORS RESPOND
Joshua A Roth, Josh J Carlson, Fang Xia, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
September 3, 2010
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice
David L Veenstra, Joshua A Roth, Louis P Garrison, et al.
Advances in Therapy
|
May 7, 2022
Correction to: Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer
Jesse A Sussell, Joshua A Roth, Craig S Meyer, et al.
Page
of 6